Battle against superbugs: which antibiotic combo works best?
NCT ID NCT07694700
First seen Jul 10, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study compares two antibiotic combinations—colistin plus meropenem versus amikacin plus meropenem—for treating multi-drug-resistant Gram-negative bacterial infections in intensive care unit patients. The goal is to see which combination is more effective at clearing the infection and improving survival, while also monitoring side effects like kidney function. The trial includes adults aged 18 to 70 admitted to the ICU with these hard-to-treat infections.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- colistin, meropenem, amikacin
- What this could lead to
- If one combination works better, it could provide a more effective treatment option for dangerous drug-resistant infections in intensive care.
- What could go wrong
- This is a single-center study with 100 participants, so results may not apply broadly. Both antibiotic combinations can cause kidney damage, which is being monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Study will include adult patient (male, female). * Patient age from 18 to 70 years. * Patient will be admitted to intensive care unit in study period (six months), who will receive intravenous colistin and meropenem or amikacin and meropenem as antimicrobial drug for treatment their MDR gram negative infection Exclusion Criteria: * Patients are admitted to intensive care unit younger than 18 years or older than 70 years. * Patients are chronic kidney disease (CKD on hemodialysis or baseline creatinine clearance (crcl) \< 10 ml/min (estimated by Cockcroft Gault equation). * Patients received renal replacement therapy before or during admission. * Patients are on any other nephrotoxic drug (vancomycin, NSAIDs, cyclosporine, amphotericin B, etc.)). * Pregnant and lactating women. * Patients refused the consent of the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDR bacteria are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beni- Suef University Hospital.
Banī Suwayf, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.